PURPOSE OF REVIEW: a)Osteoarthritis (OA) is the most common form of arthritis, and pain is the primary symptom of the disease, yet analgesic options for treating OA pain remain limited. In this review, we aimed to give an update on the current clinical and preclinical studies targeting two pathways that are being investigated for treating OA pain: the nerve growth factor (NGF) pathway and the transient receptor potential vanilloid-1 (TRPV1) pathway. RECENT FINDINGS: b)Antibodies against NGF, small molecule inhibitors of TrkA, TRPV1 agonists, and TRPV1 antagonists are all in different stages of clinical and pre-clinical testing for the treatment of OA pain. NGF antibodies have shown efficacy in the primary endpoints tested compared to placebo, however, rapidly progressive OA has been consistently observed in a subset of patients and the cause remains unclear. TRPV1 agonists have also demonstrated reduced pain with no serious adverse events - the most common adverse events include a burning or warming sensation upon administration. SUMMARY: c)Targeting the NGF and TRPV1 pathways appear effective for reducing OA pain, but further work is needed to better understand which patients may benefit most from these treatments. The anti-NGF antibody tanezumab and the TRPV1 agonist CNTX-4975 have both received fast-track designation from the FDA for the treatment of OA pain.
PURPOSE OF REVIEW: a)Osteoarthritis (OA) is the most common form of arthritis, and pain is the primary symptom of the disease, yet analgesic options for treating OA pain remain limited. In this review, we aimed to give an update on the current clinical and preclinical studies targeting two pathways that are being investigated for treating OA pain: the nerve growth factor (NGF) pathway and the transient receptor potential vanilloid-1 (TRPV1) pathway. RECENT FINDINGS: b)Antibodies against NGF, small molecule inhibitors of TrkA, TRPV1 agonists, and TRPV1 antagonists are all in different stages of clinical and pre-clinical testing for the treatment of OA pain. NGF antibodies have shown efficacy in the primary endpoints tested compared to placebo, however, rapidly progressive OA has been consistently observed in a subset of patients and the cause remains unclear. TRPV1 agonists have also demonstrated reduced pain with no serious adverse events - the most common adverse events include a burning or warming sensation upon administration. SUMMARY: c)Targeting the NGF and TRPV1 pathways appear effective for reducing OA pain, but further work is needed to better understand which patients may benefit most from these treatments. The anti-NGF antibody tanezumab and the TRPV1 agonist CNTX-4975 have both received fast-track designation from the FDA for the treatment of OA pain.
Authors: Patrick W Mantyh; Martin Koltzenburg; Lorne M Mendell; Leslie Tive; David L Shelton Journal: Anesthesiology Date: 2011-07 Impact factor: 7.892
Authors: Thomas J Schnitzer; Jean-Pierre Pelletier; Doug M Haselwood; William T Ellison; John E Ervin; Richard D Gordon; Jeffrey R Lisse; W Tad Archambault; Allan R Sampson; Heidi B Fezatte; Scott B Phillips; Joel E Bernstein Journal: J Rheumatol Date: 2011-11-15 Impact factor: 4.666
Authors: Lisa C Carlesso; Neil A Segal; Laura Frey-Law; Yuqing Zhang; Lu Na; Michael Nevitt; Core E Lewis; Tuhina Neogi Journal: Arthritis Rheumatol Date: 2019-02-07 Impact factor: 10.995
Authors: Sharon L Kolasinski; Tuhina Neogi; Marc C Hochberg; Carol Oatis; Gordon Guyatt; Joel Block; Leigh Callahan; Cindy Copenhaver; Carole Dodge; David Felson; Kathleen Gellar; William F Harvey; Gillian Hawker; Edward Herzig; C Kent Kwoh; Amanda E Nelson; Jonathan Samuels; Carla Scanzello; Daniel White; Barton Wise; Roy D Altman; Dana DiRenzo; Joann Fontanarosa; Gina Giradi; Mariko Ishimori; Devyani Misra; Amit Aakash Shah; Anna K Shmagel; Louise M Thoma; Marat Turgunbaev; Amy S Turner; James Reston Journal: Arthritis Rheumatol Date: 2020-01-06 Impact factor: 10.995